

Real-World Evidence Collaborative White Paper Citations Tracker

The Duke-Margolis Institute for Health Policy's Real-World Evidence Collaborative is proud to have its white papers cited in a diverse number of publications. The following running list of citations is current as of September 2024.

Table of Contents

A Framework for Regulatory Use of Real-World Evidence	Page 2
Characterizing RWD Quality and Relevancy for Regulatory Purposes	Page 16
Determining Real-World Data's Fitness for Use and the Role of Reliability	Page 23
Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility	Page 31
Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness	Page 34
A Roadmap for Developing Study Endpoints in Real-World Settings	Page 38
Point-of-Care Clinical Trials: Integrating Research and Care Delivery	Page 40
Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem	Page 41
Improving Patient Subgroup Representation with Real-World Data	Page 42
Lessons from Learning Health Care Systems and Recommendations for Successful Implementation	Page 43
Real-World Evidence to Support Causal Inference: Methodological Considerations for Non-Interventional Studies	Page 44

A Framework for Regulatory Use of Real-World Evidence

“The First White Paper” | Published September 2017

1. Akehurst, R., Murphy, L. A., Solà-Morales, O., Cunningham, D., Mestre-Ferrandiz, J., & de Pourville, G. (2023). Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties and a Pragmatic Way Forward. *Value in Health*. <https://doi.org/10.1016/j.jval.2023.01.010>
2. Alipour-Haris, G., Liu, X., Acha, V., Winterstein, A. G., & Burcu, M. (2024). Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases. *Clinical and Translational Science*, 17(8), e13903. <https://doi.org/10.1111/cts.13903>
3. Anderson, P., Higgins, V., Courcy, J. de, Doslikova, K., Davis, V. A., Karavali, M., & Piercy, J. (2023). Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: An update on Disease Specific Programmes. *Current Medical Research and Opinion*, 39(12), 1707–1715. <https://doi.org/10.1080/03007995.2023.2279679>
4. Antonijevic, Z., & Beckman, R. A. (2018). *Platform Trial Designs in Drug Development: Umbrella Trials and Basket Trials*. CRC Press.
5. Anzueto, A., & Kaplan, A. (2020). Dual bronchodilators in chronic obstructive pulmonary disease: Evidence from randomized controlled trials and real-world studies. *Respiratory Medicine*, X, 2, 100016. <https://doi.org/10.1016/j.yrmex.2020.100016>
6. Armağan, B., Kılıç, L., Önen, F., & Kiraz, S. (2020). Real-life parameters in rheumatology. *Ulusal Romatoloji Dergisi*, 12(Special Issue), 73–80. <https://doi.org/10.4274/raed.galenos.2020.S110>
7. Arondekar, B., Duh, M. S., Bhak, R. H., DerSarkissian, M., Huynh, L., Wang, K., Wojciehowski, J., Wu, M., Wornson, B., Niyazov, A., & Demetri, G. D. (2022). Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020. *Clinical Cancer Research*, 28(1), 27–35. <https://doi.org/10.1158/1078-0432.CCR-21-2639>
8. A.S. Kolbin & D. Yu. Belousov. (2022). Chinese experience on using RWE to support drug research, development and evaluation. *Real-World Data & Evidence*, 1(2), 17–27.
9. Barberio, J., Hernandez, R. K., Naimi, A. I., Patzer, R. E., Kim, C., & Lash, T. L. (2024). Characterizing Fit-for-Purpose Real-World Data: An Assessment of a Mother–Infant Linkage in the Japan Medical Data Center Claims Database. *Clinical Epidemiology*, 16, 31–

43. <https://doi.org/10.2147/CLEP.S429246>
10. Baumfeld Andre, E., Reynolds, R., Caubel, P., Azoulay, L., & Dreyer, N. A. (2020). Trial designs using real-world data: The changing landscape of the regulatory approval process. *Pharmacoepidemiology and Drug Safety*, 29(10), 1201–1212. <https://doi.org/10.1002/pds.4932>
11. Berkan Armagan, Levent Kilic, Fatos Onen, & Sedat Kiraz. (2020). Real-life parameters in rheumatology. *Journal of Turkish Society for Rheumatology*, 12, 73–80.
12. Bettina Schneider, Petra Maria Asprion, & Frank Grimberg. (2019). Human-centered Artificial Intelligence: A Multidimensional Approach towards Real World Evidence. In *Proceedings of the 21st International Conference on Enterprise Information Systems* (pp. 381–390). Science and Technology Publications.
13. Brown, J. P., Douglas, I. J., Hanif, S., Thwaites, R. M. A., & Bate, A. (2021). Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact. *Value in Health*, 24(9), 1241–1244. <https://doi.org/10.1016/j.jval.2021.03.020>
14. Bruxvoort, K., Sy, L. S., Luo, Y., & Tseng, H. F. (2018). Real-World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine. *American Journal of Epidemiology*, 187(9), 1856–1862. <https://doi.org/10.1093/aje/kwy076>
15. Burcu, M., Dreyer, N. A., Franklin, J. M., Blum, M. D., Critchlow, C. W., Perfetto, E. M., & Zhou, W. (2020). Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. *Pharmacoepidemiology and Drug Safety*, 29(10), 1228–1235. <https://doi.org/10.1002/pds.4975>
16. Caleigh Propes, Sarah Sheehan, & Rachele Hendricks-Sturup. (2022, May 11). *Point-of-Care Clinical Trials: Integrating Research and Care Delivery*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/point-care-clinical-trials-integrating-research-and-care-delivery>
17. Christian, J. B., Brouwer, E. S., Girman, C. J., Bennett, D., Davis, K. J., & Dreyer, N. A. (2020). Masking in Pragmatic Trials: Who, What, and When to Blind. *Therapeutic Innovation & Regulatory Science*, 54(2), 431–436. <https://doi.org/10.1007/s43441-019-00073-7>
18. Daigl, M., Abogunrin, S., Castro, F., McGough, S. F., Sturup, R. H., Boersma, C., & Abrams, K. R. (2024). Advancing the role of real-world evidence in comparative effectiveness research. *Journal of Comparative Effectiveness Research*, 0(0), e240101.

<https://doi.org/10.57264/cer-2024-0101>

19. Dang, L. E., Gruber, S., Lee, H., Dahabreh, I., Stuart, E. A., Williamson, B. D., Wyss, R., Díaz, I., Ghosh, D., Kiciman, E., Alemayehu, D., Hoffman, K. L., Vossen, C. Y., Huml, R. A., Ravn, H., Kvist, K., Pratley, R., Shih, M.-C., Pennello, G., ... Petersen, M. (2023). *A Causal Roadmap for Generating High-Quality Real-World Evidence* (No. arXiv:2305.06850). arXiv. <https://doi.org/10.48550/arXiv.2305.06850>
20. Daphne Guinn, Subha Madhavan, & Robert A. Beckman. (2018). Harnessing Real-World Data to Inform Platform Trial Design. In *Platform Trial Designs in Drug Development* (First).
21. Daubner-Bendes, R., Kovács, S., Niewada, M., Huic, M., Drummond, M., Ciani, O., Blankart, C. R., Mandrik, O., Torbica, A., Yfantopoulos, J., Petrova, G., Holownia-Voloskova, M., Taylor, R. S., Al, M., Piniashko, O., Lorenzovici, L., Tarricone, R., Zemplényi, A., & Kaló, Z. (2021). Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Frontiers in Public Health*, 8. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.612410>
22. Dayer, V. W., Drummond, M. F., Dabbous, O., Toumi, M., Neumann, P., Tunis, S., Teich, N., Saleh, S., Persson, U., von der Schulenburg, J.-M. G., Malone, D. C., Salimullah, T., & Sullivan, S. D. (2024). Real-world evidence for coverage determination of treatments for rare diseases. *Orphanet Journal of Rare Diseases*, 19(1), 47. <https://doi.org/10.1186/s13023-024-03041-z>
23. De, S., Larson, L., Kelly, K., Hanson, B., & Mack, C. D. (2021). Leveraging Real-World Evidence: A Paradigm Shift in Regulation. *Journal of Orthopaedic Trauma*, 35, S13. <https://doi.org/10.1097/BOT.0000000000002039>
24. Douglas Faries, Xiang Zhang, Zbigniew Kadziola, Uwe Siebert, Felicitas Kuehne, Robert L Obenchain, & Josep Maria Haro. (2020). Introduction to Observational and Real World Evidence Research. In *Real World Health Care Data Analysis: Causal Methods and Implementation Using SAS*. SAS Institute.
25. Dreyer, N. A. (2018). Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable. *Therapeutic Innovation & Regulatory Science*, 52(3), 362–368. <https://doi.org/10.1177/2168479018763591>
26. Dreyer, N. A., & Mack, C. D. (2023). Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice. *Pragmatic and Observational Research*, 14(null), 101–110. <https://doi.org/10.2147/POR.S396024>

27. Dron, L., Golchi, S., Hsu, G., & Thorlund, K. (2019). Minimizing control group allocation in randomized trials using dynamic borrowing of external control data – An application to second line therapy for non-small cell lung cancer. *Contemporary Clinical Trials Communications*, 16, 100446. <https://doi.org/10.1016/j.conctc.2019.100446>
28. Enogela, E. M., Buchanan, T., Carter, C. S., Elk, R., Gazaway, S. B., Goodin, B. R., Jackson, E. A., Jones, R., Kennedy, R. E., Perez-Costas, E., Zubkoff, L., Zumbro, E. L., Markland, A. D., & Buford, T. W. (2022). Preserving independence among under-resourced older adults in the Southeastern United States: Existing barriers and potential strategies for research. *International Journal for Equity in Health*, 21(1), 119. <https://doi.org/10.1186/s12939-022-01721-5>
29. Erin Hammers Forstag, Benjamin Kahn, Amanda Wagner Gee, & Carolyn Shore. (2019). *Examining the Impact of Real-World Evidence on Medical Product Development: Proceedings of a Workshop Series*. The National Academies Press. <https://nap.nationalacademies.org/catalog/25352/examining-the-impact-of-real-world-evidence-on-medical-product-development>
30. Faries, D., Zhang, X., Kadziola, Z., Siebert, U., Kuehne, F., Obenchain, R. L., & Haro, J. M. (2020). *Real World Health Care Data Analysis: Causal Methods and Implementation Using SAS*. SAS Institute.
31. Girman, C. J., Ritchey, M. E., Zhou, W., & Dreyer, N. A. (2019). Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary. *Pharmacoepidemiology and Drug Safety*, 28(4), 439–442. <https://doi.org/10.1002/pds.4697>
32. Gliklich, R. E., & Leavy, M. B. (2020). Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence. *Therapeutic Innovation & Regulatory Science*, 54(2), 303–307. <https://doi.org/10.1007/s43441-019-00058-6>
33. Grabner, M., Molife, C., Wang, L., Winfree, K. B., Cui, Z. L., Carter, G. C., & Hess, L. M. (2021). Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. *JMIR Cancer*, 7(2), e23161. <https://doi.org/10.2196/23161>
34. Gregory Daniel, Christina Silcox, Jonathan Bryan, Mark McClellan, Morgan Romine, & Katherine Frank. (2018, October 1). *Characterizing RWD Quality and Relevancy for Regulatory Purposes*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/characterizing-rwd-quality-and-relevancy-regulatory-purposes-0>

35. Guinn, D., Wilhelm, E. E., Lieberman, G., & Khozin, S. (2019). Assessing function of electronic health records for real-world data generation. *BMJ Evidence-Based Medicine*, 24(3), 95–98. <https://doi.org/10.1136/bmjebm-2018-111111>
36. Hallersten, A. M., Decker, N. M., & Huang, Y. (2023). Principles of ideal diagnostic regulation and the IVDR. *Clinical Chemistry and Laboratory Medicine (CCLM)*, 61(4), 599–607. <https://doi.org/10.1515/cclm-2022-1206>
37. Hendricks-Sturup, R. M., & Lu, C. Y. (2023). A survey of United States adult privacy perspectives and willingness to share real-world data. *Journal of Clinical and Translational Science*, 7(1), e64. <https://doi.org/10.1017/cts.2023.4>
38. Hendricks-Sturup, R. M., Zhang, F., & Lu, C. Y. (2022). A Survey of Research Participants' Privacy-Related Experiences and Willingness to Share Real-World Data with Researchers. *Journal of Personalized Medicine*, 12(11), Article 11. <https://doi.org/10.3390/jpm12111922>
39. Hi Gin Sung, Han-Heui Park, Gyu-Won Jung, & Ju-Young Shin. (2020). Current Status and Examples of US FDA or EMA's Regulatory Decision using Real World Data/Real World Evidence. *Yakhak Hoeji*, 64(2).
40. *ISPOR 2022-2023 Top 10 HEOR Trends Report*. (2022). ISPOR. <https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends>
41. Jaksá, A., Wu, J., Jónsson, P., Eichler, H.-G., Vititoe, S., & Gatto, N. M. (2021). Organized structure of real-world evidence best practices: Moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*, 10(9), 711–731. <https://doi.org/10.2217/ce-2020-0228>
42. Jeff Andrews. (2019, November). *Evidence Generation for Screening and Diagnostic Tests and Algorithms*. 9th International Conference for EBHC Teachers and Developers. https://www2.ebhconference.org/previous_editions/2019/posters/Andrews_J.pdf
43. Jemielita, T., Li, X. (Nicole), Burke, T., Liaw, K.-L., Zhou, W., & Chen, C. (2021). Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab. *JCO Clinical Cancer Informatics*, 5, 849–858. <https://doi.org/10.1200/CCI.21.00042>
44. Jiang, D., Chen, K., Mukhopadhyay, S., Katta, N., & Zhang, L. (2019). Review of Statistical Issues in Pragmatic Clinical Trials in Current Drug Development Environment. In L. Zhang, D.-G. (Din) Chen, H. Jiang, G. Li, & H. Quan (Eds.), *Contemporary Biostatistics with Biopharmaceutical Applications* (pp. 285–298). Springer International Publishing.

https://doi.org/10.1007/978-3-030-15310-6_16

45. Jie Chen, Hongbo Yuan, Haijun Tian, & Kristijan Kahler. (2022, July). *Guidance on the Design and Protocol Development of Real-World Studies for Drugs (DRAFT)*. Center for Drug Evaluation (CDE) National Medical Products Administration of China.
[http://www.gdbiost.org/uploads/files/Guidance%20on%20the%20Design%20and%20Protocol%20Development%20of%20Real-World%20Studies\(Draft\).pdf](http://www.gdbiost.org/uploads/files/Guidance%20on%20the%20Design%20and%20Protocol%20Development%20of%20Real-World%20Studies(Draft).pdf)
46. Ji-Hwan Bae, Han-Heui Park, Gyu-Won Jung, Hi Gin Sung, Jiyong Yang, JungEun Hwang, Dongwon Yoon, Yunha Noh, & Ju-Young Shin. (2019). Establishment of Framework for the Development and Review of Drugs Based on Real-World Data/Real-World Evidence. *약물역학위해관리학회지*, 11, 62–71.
47. Jiyeon Kang. (2022). Real-World Data in Health Technology Assessment: Do We Know It Well Enough? In *Precision Oncology and Cancer Biomarkers* (Vol. 5). Springer.
48. Jormanainen, V. (2019). Valtakunnallisten Kanta-palvelujen käyttöönotto apteekkeissa ja kuntien julkisessa perusterveydenhuollossa vuosina 2010–2016. *Finnish Journal of eHealth and eWelfare*, 11(3), Article 3. <https://doi.org/10.23996/fjhw.77601>
49. Katkade, V. B., Sanders, K. N., & Zou, K. H. (2018). Real world data: An opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. *Journal of Multidisciplinary Healthcare*, 11, 295–304.
<https://doi.org/10.2147/JMDH.S160029>
50. Kc, S., Lin, L. W., Bayani, D. B. S., Zemlyanska, Y., Adler, A., Ahn, J., Chan, K., Choiphel, D., Genuino-Marfori, A. J., Kearney, B., Liu, Y., Nakamura, R., Pearce, F., Prinja, S., Pwu, R.-F., Shafie, A. A., Sui, B., Suwantika, A., Tunis, S., ... Wee, H.-L. (2023). What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward. *International Journal of Health Policy and Management*, 12(Issue 1), 1–9.
<https://doi.org/10.34172/ijhpm.2023.6858>
51. Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, Christina Silcox, Morgan Romine, Kathryn Lallinger, Adam Kroetsch, Huzyfa Fazili, Marta Wosinska, & Mark McClellan. (2020, August 28). *A Roadmap for Developing Study Endpoints in Real-World Settings*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/roadmap-developing-study-endpoints-real-world-settings>
52. Khosla, S., White, R., Medina, J., Ouwens, M., Emmas, C., Koder, T., Male, G., & Leonard, S. (2018). Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? *F1000Research*, 7, 111.

<https://doi.org/10.12688/f1000research.13585.2>

53. Klonoff, D. C. (2020). The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. *Journal of Diabetes Science and Technology*, 14(2), 345–349. <https://doi.org/10.1177/1932296819832661>
54. Kraus, V. B., Simon, L. S., Katz, J. N., Neogi, T., Hunter, D., Guermazi, A., & Karsdal, M. A. (2019). Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs. *Osteoarthritis and Cartilage*, 27(4), 571–579. <https://doi.org/10.1016/j.joca.2018.11.002>
55. Kugener, V. F., Freedland, E. S., Maynard, K. I., Aimer, O., Webster, P. S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. *Drug Safety*, 44(8), 843–852. <https://doi.org/10.1007/s40264-021-01078-8>
56. Lai, E. C.-C., Lin, T.-C., Lange, J. L., Chen, L., Wong, I. C. K., Sing, C.-W., Cheung, C.-L., Shao, S.-C., & Yang, Y.-H. K. (2022). Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: A retrospective cohort study. *Osteoporosis International*, 33(5), 1155–1164. <https://doi.org/10.1007/s00198-021-06291-w>
57. Lauren Elizabeth Eyler Dang. (2023). *Development and Application of the Experiment-Selector Cross-Validated Targeted Maximum Likelihood Estimator* [University of California, Berkeley]. <https://www.proquest.com/docview/2869145998?pq-origsite=gscholar&fromopenview=true&sourcetype=Dissertations%20&%20Theses>
58. Li, W., Fan, H., Tang, J., Wang, Q., Zhang, X., & El-Awady, J. A. (2019). Effects of alloying on deformation twinning in high entropy alloys. *Materials Science and Engineering: A*, 763, 138143. <https://doi.org/10.1016/j.msea.2019.138143>
59. Ligang Luo, Pingyan Chen, Jianing Di, Jun Wang, & Chunquan Ou. (2021, April). *Guideline on Using Real-World Data to Generate Real-World Evidence (Trial Version)*. Center for Drug Evaluation, NMPA. <http://www.gdbiost.org/uploads/files/%E3%80%8AGuideline%20on%20Using%20Real-World%20Data%20to%20Generate%20Real-World%20Evidence%E3%80%8B-RWD%E8%AF%95%E8%A1%8C.pdf>
60. Lim, R., Lee, D. K., Sabourin, P., Ferguson, J., Metcalf, M., Smith, M., Corriol-Rohou, S., Eichler, H.-G., Lumpkin, M., Hirsch, G., Chen, I. M., O'Rourke, B., Schiel, A., Crabb, N., Aronson, N., Pezalla, E., Boutin, M., Binder, L., & Wilhelm, L. (2019). Recognizing that

Evidence is Made, not Born. *Clinical Pharmacology & Therapeutics*, 105(4), 844–856.
<https://doi.org/10.1002/cpt.1317>

61. Lin, X., Li, G., & Quan, H. (2022). Strategy for Combining Information from Real World Data Sources When Individual Patient Data Are Not Simultaneously Accessible. *Statistics in Biopharmaceutical Research*, 14(4), 456–462.
<https://doi.org/10.1080/19466315.2022.2063170>
62. Ling, A. Y., Jreich, R., Montez-Rath, M. E., Meng, Z., Kapphahn, K., Chandross, K. J., & Desai, M. (2022). Transporting observational study results to a target population of interest using inverse odds of participation weighting. *PLOS ONE*, 17(12), e0278842.
<https://doi.org/10.1371/journal.pone.0278842>
63. LoCasale, R. J., Pashos, C. L., Gutierrez, B., Dreyer, N. A., Collins, T., Calleja, A., Seewald, M. J., Plumb, J. M., Liwing, J., Tepie, M. F., & Khosla, S. (2021). Bridging the Gap Between RCTs and RWE Through Endpoint Selection. *Therapeutic Innovation & Regulatory Science*, 55(1), 90–96. <https://doi.org/10.1007/s43441-020-00193-5>
64. Lopez, M. H., McClellan, M. B., & Daniel, G. (2024). Perspectives on Improving Value Assessment With the ISPOR SUITABILITY Checklist. *Value in Health*, 27(6), 687–688.
<https://doi.org/10.1016/j.jval.2024.04.020>
65. Lydia Wenxin Lin, Jeonghoon Ahn, Diana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Wandrudee Isaranuwatthai, Sarin KC, Brendon Kearney, Jing Lou, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh-Fang PWU, Asrul Akmal Shafie, Yot Teerawattananon, Sean Tunis, Hui-Min Wu, John Zalcborg, & Hwee-Lin Wee. (2020, November 1). *Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia*. REALISE Group. https://hiper.nus.edu.sg/wp-content/uploads/2021/03/REALISE-Full-guidance-post-feedback_20201211-version-1.1.pdf
66. Marc Berger, Greg Daniel, Katherine Frank, Adrian Hernandez, Mark McClellan, Sally Okun, Marc Overhage, Richard Platt, Morgan Romine, Sean Tunis, & Marcus Wilson. (2017, September 13). *A Framework for Regulatory Use of Real-World Evidence*. Duke-Margolis Center for Health Policy.
<https://healthpolicy.duke.edu/publications/framework-regulatory-use-real-world-evidence>
67. Marc Berger, James Li, William Crown, & Kelly Zou. (2023). *ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making*. <https://doi.org/10.21203/rs.3.rs-3025202/v1>

68. Milla Kajanne. (2021). *Tosielaman tiedon hyodyntaminen sairaalassa—Tiedolla johtaminen ja sen kehittäminen kohti vaikuttavuusperusteista terveydenhuoltoa*.
<https://helda.helsinki.fi/server/api/core/bitstreams/e4b9d9a8-dfcd-4cb9-b58e-8c2ec6e33ef2/content>
69. Mofid, S., Bolisli, W. R., & Kühler, T. C. (2022). Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. *Clinical Therapeutics*, 44(2), 306–322.
<https://doi.org/10.1016/j.clinthera.2021.12.010>
70. Neil A. Belson. (2018). *FDA’s Historical Use of “Real World Evidence.”* FDLI.
https://heinonline.org/HOL/Page?handle=hein.journals/fdliup2018&div=45&g_sent=1&asa_token=&collection=journals
71. Neil A Belson. (2020). Emergence of Real World Evidence in Precision Medicine. In *The Road from Nanomedicine to Precision Medicine* (First). Jenny Stanford Publishing.
72. Nicola Sawalhi-Leckenby, Sofia Fernandes, & Vernon Schabert. (2019, Fall). *The Evidence Forum: Navigating the Path to Approval and Access: Research Operations for Secondary Use of Clinical Sites’ EMR*. Evidera. https://www.evidera.com/wp-content/uploads/2019/10/FINAL_The-Evidence-Forum_Fall_2019.pdf#page=33
73. Nicole Rodrigues. (2019). Real World Evidence: Impact on Clinical Data. *Data Basics*, 25(1). <https://scdm.org/wp-content/uploads/2019/12/1.pdf#page=18>
74. Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas Harisson, Adam Aten, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, September 26). *Determining Real-World Data’s Fitness for Use and the Role of Reliability*. Duke-Margolis Center for Health Policy.
<https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>
75. Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, Katherine Frank, Morgan Romine, Adam Kroetsch, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, November 25). *Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility*. Duke-Margolis Center for Health Policy.
<https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world>
76. Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam Kroetsch, Katherine Frank, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, December 19). *Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed*

Product Effectiveness. Duke-Margolis Center for Health Policy.

<https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product>

77. Oksen, D., Prince, P., Boutmy, E., Garry, E. M., Ellers-Lenz, B., Estrin, A., Johne, A., Verpillat, P., & Gatto, N. M. (2022). Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study. *Clinical and Translational Science*, 15(8), 1990–1998. <https://doi.org/10.1111/cts.13315>
78. O’Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
79. Olson, W. H., & Turkoz, I. (n.d.). Up-front matching: An ongoing recruitment method for prospective observational studies that mimics randomization for selected baseline covariates. *Journal of Biopharmaceutical Statistics*, 1–14. <https://doi.org/10.1080/10543406.2024.2373436>
80. O’Neill, T., Miksad, R., Miller, D., Maloney, L., John, A., Hiller, C., & Hornberger, J. (2019). ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products. *Value in Health*, 22(7), 754–761. <https://doi.org/10.1016/j.jval.2019.03.020>
81. Quazi, S., Narang, C., Espinoza, J. C., & Bourgeois, F. T. (2023). Characteristics and Results of Pediatric Medical Device Studies: 2017–2022. *Pediatrics*, 152(3), e2022059842. <https://doi.org/10.1542/peds.2022-059842>
82. Rachele Hendricks-Sturup & Dixil Francis. (2023). Evidence on Real-World Data and Real-World Evidence As a Driver for Precision Medicine Implementation in Pharmacy Practice. In *Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy*. Springer, Cham. https://doi.org/10.1007/978-3-030-50247-8_93-1
83. Raman, S. R., Curtis, L. H., Temple, R., Andersson, T., Ezekowitz, J., Ford, I., James, S., Marsolo, K., Mirhaji, P., Rocca, M., Rothman, R. L., Sethuraman, B., Stockbridge, N., Terry, S., Wasserman, S. M., Peterson, E. D., & Hernandez, A. F. (2018). Leveraging electronic health records for clinical research. *American Heart Journal*, 202, 13–19. <https://doi.org/10.1016/j.ahj.2018.04.015>
84. Raman, S. R., O’Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>

85. Rebecca Ray, Trevan Locke, & Rachele Hendricks-Sturup. (2022, July 20). *Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/aligning-shared-evidentiary-needs-among-payers-and-regulators-real-world-data>

86. Richard E. Gliklich, Michelle B. Leavy, & Nancy A. Dreyer. (2019). *Registries for Evaluating Patient Outcomes: A User's Guide: Addendum 2—Tools for Registry Interoperability*. AHRQ. https://web.archive.org/web/20200506073435id_/https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-registries-users-guide-third-edition-second-addendum.pdf

87. Robert S. Miller, Kristi Mitchell, Rachel Myslinski, & Josh Rising. (2019). Health Information Technology (IT) and Patient Registries. In *Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User's Guide* (3rd ed.). Agency for healthcare Research and Quality. <https://www.ncbi.nlm.nih.gov/books/NBK551883/>

88. Roberts, M. H., & Ferguson, G. T. (2021). Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. *PharmacoEconomics - Open*, 5(1), 3–11. <https://doi.org/10.1007/s41669-020-00221-y>

89. Roig Izquierdo, M., Prat Casanovas, M. A., Gorgas Torner, M. Q., & Pontes García, C. (2020). Registro de pacientes y tratamientos de medicamentos hospitalarios en Cataluña: 10 años de datos clínicos. *Medicina Clínica*, 154(5), 185–191. <https://doi.org/10.1016/j.medcli.2019.09.009>

90. Rosenberg, M., Sheehan, S., Zhou, E., Pinnow, E., Burnell, J., Romine, M., & Dal Pan, G. (2020). FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes. *Pharmacoepidemiology and Drug Safety*, 29(9), 1022–1029. <https://doi.org/10.1002/pds.5073>

91. Rudrapatna, V. A., & Butte, A. J. (2020). Opportunities and challenges in using real-world data for health care. *The Journal of Clinical Investigation*, 130(2), 565–574. <https://doi.org/10.1172/JCI129197>

92. Samson, S. I., Konty, K., Lee, W.-N., Quisel, T., Foschini, L., Kerr, D., Liska, J., Mills, H., Hollingsworth, R., Greenberg, M., & Beal, A. C. (2021). Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact. *Journal of Diabetes Science and Technology*, 15(1), 44–52. <https://doi.org/10.1177/1932296819883340>

93. Santiago Hasdeu, Ernesto Ruiz, Guadalupe Montero, Daiana Campo, & Eliana Carrasco. (2024). Farmacoepidemiología y costos del tratamiento de la artritis reumatoidea en

base a datos de la vida real de la provincia argentina de Neuquen: Estudio descripto (anos 2012-2023). *Revista De Salud Publica*, 30(1).

<https://doi.org/10.31052/1853.1180.v30.n1.42890>

94. Sarri, G., Patorno, E., Yuan, H., Guo, J. (Jeff), Bennett, D., Wen, X., Zullo, A. R., Largent, J., Panaccio, M., Gokhale, M., Moga, D. C., Ali, M. S., & Debray, T. P. A. (2022). Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evidence-Based Medicine*, 27(2), 109–119. <https://doi.org/10.1136/bmjebm-2020-111493>
95. Segal J, Levy J, DiStefano M, Sharma, R, Zhang A, Kodavarti N, & Bass E. (2022, November). *Analysis of Requirements for Coverage With Evidence Development (CED)—Topic Refinement*. Agency for healthcare Research and Quality. <https://effectivehealthcare.ahrq.gov/products/coverage-evidence-development/research-report>
96. Seifu, Y., Gamalo-Siebers, M., Barthel, F. M.-S., Lin, J., Qiu, J., Cooner, F., Ruan, S., & Walley, R. (2020). Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review. *Therapeutic Innovation & Regulatory Science*, 54(6), 1436–1443. <https://doi.org/10.1007/s43441-020-00170-y>
97. Shapiro, A., Bradshaw, B., Landes, S., Kammann, P., Bois De Fer, B., Lee, W.-N., & Lange, R. (2021). A novel digital approach to describe real world outcomes among patients with constipation. *Npj Digital Medicine*, 4(1), Article 1. <https://doi.org/10.1038/s41746-021-00391-x>
98. Stewart, M., Norden, A. D., Dreyer, N., Henk, H. J., Abernethy, A. P., Chrischilles, E., Kushi, L., Mansfield, A. S., Khozin, S., Sharon, E., Arunajadai, S., Carnahan, R., Christian, J. B., Miksad, R. A., Sakoda, L. C., Torres, A. Z., Valice, E., & Allen, J. (2019). An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. *JCO Clinical Cancer Informatics*, 3, 1–15. <https://doi.org/10.1200/CCI.18.00155>
99. Sung, H. G., Park, H.-H., Jung, G.-W., & Shin, J.-Y. (2020). Current Status and Examples of US FDA or EMA's Regulatory Decision using Real World Data/Real World Evidence. *Yakhak Hoeji*, 64(2), 136–155. <https://doi.org/10.17480/psk.2020.64.2.136>
100. Tan, G. S. Q., Sloan, E. K., Lambert, P., Kirkpatrick, C. M. J., & Ilomäki, J. (2023). Drug repurposing using real-world data. *Drug Discovery Today*, 28(1), 103422. <https://doi.org/10.1016/j.drudis.2022.103422>

101. Thakur, S. (2023). Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype? *Indian Journal of Surgical Oncology*. <https://doi.org/10.1007/s13193-023-01784-y>
102. Timbie, J. W., Kim, A. Y., Baker, L., Li, R., & W Concannon, T. (2024). Lessons on the use of real-world data in medical device research: Findings from the National Evaluation System for Health Technology Test-Cases. *Journal of Comparative Effectiveness Research*, 13(9), e240078. <https://doi.org/10.57264/cer-2024-0078>
103. van den Heuvel, T., Castañeda, J., Arrieta, A., Voelker, B., Cohen, O., Liu, M., Diaz Garelli, F., & Shin, J. (2024). Generating real-world evidence on diabetes technology using the CareLink Personal data management system. *Diabetes, Obesity and Metabolism*, 26(11), 4846–4853. <https://doi.org/10.1111/dom.15868>
104. Varnai, P., Davé, A., Farla, K., Nooijen, A., & Petrosova, L. (2021). The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry. *Clinical Pharmacology & Therapeutics*, 110(5), 1180–1189. <https://doi.org/10.1002/cpt.2103>
105. Villines, T. C., Cziraky, M. J., & Amin, A. N. (2020). Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making. *Clinical Medicine Insights: Cardiology*, 14, 1179546820953410. <https://doi.org/10.1177/1179546820953410>
106. W. Nicholson Price II. (2018). Drug Approval in a Learning Health System. *Minnesota Law Review*, 102(6), 2413–2462.
107. Wang, J., Chen, J., Zhao, J., Wu, Y., Xin, X., & Chen, P. (2024). Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>
108. Wang, S. V., Sreedhara, S. K., & Schneeweiss, S. (2022). Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. *Nature Communications*, 13(1), Article 1. <https://doi.org/10.1038/s41467-022-32310-3>
109. Webster, J., & Smith, B. D. (2019). The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. *Clinical Therapeutics*, 41(2), 336–349. <https://doi.org/10.1016/j.clinthera.2018.12.013>
110. Weng, X. (2018). Real-world evidence approach to traditional herbal medicinal products. *Drug Discovery Today*, 23(7), 1321–1323.

<https://doi.org/10.1016/j.drudis.2018.05.008>

111. Wise, J., Möller, A., Christie, D., Kalra, D., Brodsky, E., Georgieva, E., Jones, G., Smith, I., Greiffenberg, L., McCarthy, M., Arend, M., Luttringer, O., Kloss, S., & Arlington, S. (2018). The positive impacts of Real-World Data on the challenges facing the evolution of biopharma. *Drug Discovery Today*, 23(4), 788–801. <https://doi.org/10.1016/j.drudis.2018.01.034>
112. Xia, A. D., Schaefer, C. P., Szende, A., Jahn, E., & Hirst, M. J. (2019). RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design. *Drugs - Real World Outcomes*, 6(4), 193–203. <https://doi.org/10.1007/s40801-019-00167-6>
113. Yang, H.-S., Kim, S.-Y., & Park, J.-H. (2023). Development and Utilization of Drug Lifecycle Data in the United States, Japan, and Europe. *Journal of Health Informatics and Statistics*, 48(2), 148–156. <https://doi.org/10.21032/jhis.2023.48.2.148>
114. Zhu, M., Sridhar, S., Hollingsworth, R., Chit, A., Kimball, T., Murmello, K., Greenberg, M., Gurunathan, S., & Chen, J. (2020). Hybrid clinical trials to generate real-world evidence: Design considerations from a sponsor’s perspective. *Contemporary Clinical Trials*, 94, 105856. <https://doi.org/10.1016/j.cct.2019.105856>
115. Zhu, R., Vora, B., Menon, S., Younis, I., Dwivedi, G., Meng, Z., Datta-Mannan, A., Manchandani, P., Nayak, S., Tammara, B. K., Garhyan, P., Iqbal, S., Dagenais, S., Chanu, P., Mukherjee, A., Ghobadi, C., & International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Real-World Data Working Group. (n.d.). Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval—An Industry Perspective. *Clinical Pharmacology & Therapeutics*, n/a(n/a). <https://doi.org/10.1002/cpt.2988>
116. Zura, R., Irwin, D. E., Mack, C. D., Aldridge, M. L., & Mackowiak, J. I. (2021). Real-World Evidence: A Primer. *Journal of Orthopaedic Trauma*, 35, S1. <https://doi.org/10.1097/BOT.0000000000002037>
117. Сергеевич, К. А., & Юрьевич, Б. Д. (2022). КИТАЙСКИЙ ОПЫТ ПО ИСПОЛЬЗОВАНИЮ ДОКАЗАТЕЛЬСТВ, ПОЛУЧЕННЫХ НА ОСНОВЕ ДАННЫХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ В ПРОЦЕССЕ РАЗРАБОТКИ, ИССЛЕДОВАНИЯ И ОЦЕНКИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ. *Реальная клиническая практика: данные и доказательства*, 2(1), Article 1.

Characterizing RWD Quality and Relevancy for Regulatory Purposes

“The Data Quality Paper” | Published October 2018

1. Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021). Cardiovascular Safety and Superiority of Anti-Obesity Medications. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 14, 3199–3208. <https://doi.org/10.2147/DMSO.S311359>
2. Bando, H., Tajima, E., Aoyagi, Y., Ng, D., Mizuguchi, K., Suzuki, M., Takeda, Y., Misumi, T., Brown, L., Murchison, M., Lamba, V., Zeng, Y., Froment, M., Jung, J., Fedak, K., Wang, B., Yoshino, T., & Ohtsu, A. (2023). The emerging role of real-world data in oncology care in Japan. *ESMO Real World Data and Digital Oncology*, 2, 100005. <https://doi.org/10.1016/j.esmorw.2023.100005>
3. Beyrer, J. (2023). *Regulatory Acceptable Real-World Effectiveness Endpoints: How Clarity Can Best Be Achieved in the United States* [Ph.D., Indiana University - Purdue University Indianapolis]. <https://www.proquest.com/docview/2908925189/abstract/2FBBFAB790144CA3PQ/1>
4. Beyrer, J., Abedtash, H., Hornbuckle, K., & Murray, J. F. (2022). A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*, 11(7), 499–511. <https://doi.org/10.2217/cer-2022-0006>
5. Bhatt, A. (2023). Data quality – The foundation of real-world studies. *Perspectives in Clinical Research*, 14(2), 92–94. https://doi.org/10.4103/picr.picr_12_23
6. Bourla, A. B., & Meropol, N. J. (2021). Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform. *DIGITAL HEALTH*, 7, 20552076211059975. <https://doi.org/10.1177/20552076211059975>
7. Brown, J. P., Douglas, I. J., Hanif, S., Thwaites, R. M. A., & Bate, A. (2021). Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact. *Value in Health*, 24(9), 1241–1244. <https://doi.org/10.1016/j.jval.2021.03.020>
8. Burcu, M., Dreyer, N. A., Franklin, J. M., Blum, M. D., Critchlow, C. W., Perfetto, E. M., & Zhou, W. (2020). Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. *Pharmacoepidemiology and Drug Safety*, 29(10), 1228–1235. <https://doi.org/10.1002/pds.4975>
9. Burns, L., Roux, N. L., Kalesnik-Orszulak, R., Christian, J., Hukkelhoven, M., Rockhold, F.,

- & O'Donnell, J. (2022). Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World. *Clinical Therapeutics*, 44(3), 420–437. <https://doi.org/10.1016/j.clinthera.2022.01.012>
10. Castellanos, E. H., Wittmershaus, B. K., & Chandwani, S. (2024). Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions. *JCO Clinical Cancer Informatics*, 8, e2300046. <https://doi.org/10.1200/CCI.23.00046>
 11. Curtis, L. H., Sola-Morales, O., Heidt, J., Saunders-Hastings, P., Walsh, L., Casso, D., Oliveria, S., Mercado, T., Zusterzeel, R., Sobel, R. E., Jalbert, J. J., Mastey, V., Harnett, J., & Quek, R. G. W. (n.d.). Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls. *Clinical Pharmacology & Therapeutics*, n/a(n/a). <https://doi.org/10.1002/cpt.2913>
 12. Daniel, G. (2019). Building Trust in RWE Will Support Clearer Regulatory Uses. *Therapeutic Innovation & Regulatory Science*, 53(4), 417–419. <https://doi.org/10.1177/2168479019859948>
 13. Dreyer, N. A., Mack, C. D., Anderson, R. B., Wojtys, E. M., Hershman, E. B., & Sills, A. (2019). Lessons on Data Collection and Curation From the NFL Injury Surveillance Program. *Sports Health*, 11(5), 440–445. <https://doi.org/10.1177/1941738119854759>
 14. *FDA-NIH Terminology for Clinical Research: Glossary of Terms and Definitions*. (2024, May). FDA-NIH Clinical Research Working Group. https://osp.od.nih.gov/wp-content/uploads/2024/05/Glossary-Terms-for-RFI_Final_Draft.pdf
 15. Fleurence, R. L., Kent, S., Adamson, B., Tcheng, J., Balicer, R., Ross, J. S., Haynes, K., Muller, P., Campbell, J., Bouée-Benhamiche, E., García Martí, S., & Ramsey, S. (2024). Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force. *Value in Health*, 27(6), 692–701. <https://doi.org/10.1016/j.jval.2024.01.019>
 16. Franklin, J. M., Glynn, R. J., Martin, D., & Schneeweiss, S. (2019). Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. *Clinical Pharmacology & Therapeutics*, 105(4), 867–877. <https://doi.org/10.1002/cpt.1351>
 17. Gatto, N. M., Campbell, U. B., Rubinstein, E., Jaksa, A., Mattox, P., Mo, J., & Reynolds, R. F. (2022). The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework. *Clinical Pharmacology & Therapeutics*, 111(1), 122–134. <https://doi.org/10.1002/cpt.2466>
 18. Girman, C. J., Ritchey, M. E., & Lo Re, V. (2022). Real-world data: Assessing electronic

health records and medical claims data to support regulatory decision-making for drug and biological products. *Pharmacoepidemiology and Drug Safety*, 31(7), 717–720. <https://doi.org/10.1002/pds.5444>

19. Girman, C. J., Ritchey, M. E., Zhou, W., & Dreyer, N. A. (2019). Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary. *Pharmacoepidemiology and Drug Safety*, 28(4), 439–442. <https://doi.org/10.1002/pds.4697>
20. Gregory Daniel, Christina Silcox, Jonathan Bryan, Mark McClellan, Morgan Romine, & Katherine Frank. (2018, October 1). *Characterizing RWD Quality and Relevancy for Regulatory Purposes*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/characterizing-rwd-quality-and-relevancy-regulatory-purposes-0>
21. Gressler, L. E. (2021). *The Creation of Objective Performance Criteria and Generation of Predictive Models among Medical Devices in a Vascular Space* [Ph.D., University of Maryland, Baltimore]. <https://www.proquest.com/docview/2537953650/abstract/5983EFA19019497EPQ/1>
22. Gressler, L. E., Link to external site, this link will open in a new window, Marinac-Dabic, D., dosReis, S., Goodney, P., Link to external site, this link will open in a new window, Mullins, C. D., & Shaya, F. (2022). Creation of objective performance criteria among medical devices. *BMJ Surgery, Interventions, & Health Technologies*, 4(1), e000106. <https://doi.org/10.1136/bmjst-2021-000106>
23. Hanson, G., Chitnis, T., Williams, M. J., Gan, R. W., Julian, L., Mace, K., Chia, J., Wormser, D., Martinec, M., Astorino, T., Leviner, N., Maung, P., Jan, A., & Belendiuk, K. (2022). Generating real-world data from health records: Design of a patient-centric study in multiple sclerosis using a commercial health records platform. *JAMIA Open*, 5(1), ooab110. <https://doi.org/10.1093/jamiaopen/ooab110>
24. He, W., Fang, Y., Wang, H., & Chan, I. (2021). Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*, 0(0), 1–12. <https://doi.org/10.1080/19466315.2021.1927827>
25. He, W., Zhang, Z., & Dharmarajan, S. (2023). Assessment of Fit-for-Use Real-World Data Sources and Applications. In W. He, Y. Fang, & H. Wang (Eds.), *Real-World Evidence in Medical Product Development* (pp. 45–61). Springer International Publishing. https://doi.org/10.1007/978-3-031-26328-6_4
26. Hou, J., Zhao, R., Gronsbell, J., Beaulieu-Jones, B. K., Webber, G., Jemielita, T., Wan, S.,

- Hong, C., Lin, Y., Cai, T., Wen, J., Panickan, V. A., Bonzel, C.-L., Liaw, K.-L., Liao, K. P., & Cai, T. (2022). *Harnessing electronic health records for real-world evidence* (No. arXiv:2211.16609). arXiv. <https://doi.org/10.48550/arXiv.2211.16609>
27. Hou, J., Zhao, R., Gronsbell, J., Lin, Y., Bonzel, C.-L., Zeng, Q., Zhang, S., Beaulieu-Jones, B. K., Weber, G. M., Jemielita, T., Wan, S. S., Hong, C., Cai, T., Wen, J., Panickan, V. A., Liaw, K.-L., Liao, K., & Cai, T. (2023). Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies. *Journal of Medical Internet Research*, 25(1), e45662. <https://doi.org/10.2196/45662>
28. Jackson, M. L., Manickam, R., Derieg, D., Gombar, S., & Low, Y. S. (2024). *Quantifying Fit-for-Purpose in Real World Data: Data Grading and FitQ Scores* (p. 2024.02.02.24302239). medRxiv. <https://doi.org/10.1101/2024.02.02.24302239>
29. Jennifer R. Popovic. (2019). *Real-world data as real-world evidence: Establishing the meaning of data as a prerequisite to determining secondary-use value*. PharaSUG2019. <https://www.lexjansen.com/pharmasug/2019/RW/PharmaSUG-2019-RW-310.pdf>
30. Kugener, V. F., Freedland, E. S., Maynard, K. I., Aimer, O., Webster, P. S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. *Drug Safety*, 44(8), 843–852. <https://doi.org/10.1007/s40264-021-01078-8>
31. L. (Luuk) Bongers. (2024). *Including Children with High-Grade CNS Tumors in Existing Labels: The Possibilities of Real-World Evidence* [Utrecht University]. <https://studenttheses.uu.nl/bitstream/handle/20.500.12932/45785/Including%20Children%20with%20High%20Grade%20CNS%20Tumors%20in%20Existing%20Labels%20The%20Possibilities%20of%20Real%20World%20Evidence.pdf?sequence=1>
32. Lesley Curtis, Jeffrey S Brown, John Laschinger, Aaron Lottes, Keith Marsolo, Frederick A. Masoudi, Joseph S Ross, Art Sedrakyan, Kara Southall, James E Tcheng, Karen Ullisney, & Charles Viviano. (2020, February). *National Evaluation System for health Technology Coordinating Center (NESTcc) Data Quality Framework*. NEST Coordinating Center. <https://mdic.org/wp-content/uploads/2020/02/NESTcc-Data-Quality-Framework.pdf>
33. Levenson, M., He, W., Chen, L., Dharmarajan, S., Izem, R., Meng, Z., Pang, H., & Rockhold, F. (2022). Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development. *Statistics in Biopharmaceutical Research*, 0(0), 1–8. <https://doi.org/10.1080/19466315.2022.2120533>
34. Ligang Luo, Pingyan Chen, Jianing Di, Jun Wang, & Chunquan Ou. (2021, April). *Guideline*

on Using Real-World Data to Generate Real-World Evidence (Trial Version). Center for Drug Evaluation, NMPA.

<http://www.gdbiost.org/uploads/files/%E3%80%8AGuideline%20on%20Using%20Real-World%20Data%20to%20Generate%20Real-World%20Evidence%E3%80%8B-RWD%E8%AF%95%E8%A1%8C.pdf>

35. Lopez, M. H., McClellan, M. B., & Daniel, G. (2024). Perspectives on Improving Value Assessment With the ISPOR SUIABILITY Checklist. *Value in Health*, 27(6), 687–688. <https://doi.org/10.1016/j.jval.2024.04.020>
36. Marc Berger, James Li, William Crown, & Kelly Zou. (2023). *ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making*. <https://doi.org/10.21203/rs.3.rs-3025202/v1>
37. Marsolo, K., Curtis, L., Qualls, L., Xu, J., Zhang, Y., Phillips, T., Hill, C. L., Sanders, G., Maro, J. C., Kiernan, D., Draper, C., Coughlin, K., Dutcher, S. K., Hernández-Muñoz, J. J., & Falconer, M. (n.d.). Assessing the harmonization of structured electronic health record data to reference terminologies and data completeness through data provenance. *Learning Health Systems*, n/a(n/a), e10468. <https://doi.org/10.1002/lrh2.10468>
38. Muntner, P., Hernandez, R. K., Kent, S. T., Browning, J. E., Gilbertson, D. T., Hurwitz, K. E., Jick, S. S., Lai, E. C., Lash, T. L., Monda, K. L., Rothman, K. J., Bradbury, B. D., & Brookhart, M. A. (2024). Staging and clean room: Constructs designed to facilitate transparency and reduce bias in comparative analyses of real-world data. *Pharmacoepidemiology and Drug Safety*, 33(3), e5770. <https://doi.org/10.1002/pds.5770>
39. Okun, S. (2019). The Missing Reality of Real Life in Real-World Evidence. *Clinical Pharmacology & Therapeutics*, 106(1), 136–138. <https://doi.org/10.1002/cpt.1465>
40. O’Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
41. O’Neill, T., Miksad, R., Miller, D., Maloney, L., John, A., Hiller, C., & Hornberger, J. (2019). ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products. *Value in Health*, 22(7), 754–761. <https://doi.org/10.1016/j.jval.2019.03.020>
42. Purpura, C. A., Garry, E. M., Honig, N., Case, A., & Rassen, J. A. (2022). The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. *Clinical Pharmacology & Therapeutics*, 111(1), 135–144. <https://doi.org/10.1002/cpt.2474>

43. Rachael L. DiSantostefano, Erica A Voss, & Clair Blacketer. (2020). "Fake News" in the Rush to Inform on COVID-19: How Research Retraction Can Inform Best Practices for Real-World Data Quality and Reporting. Janssen Research and Development. https://www.ohdsi.org/wp-content/uploads/2020/10/DiSantostefano-Abstract_COVID19-Retractions-Inform-RWD-Quality-and-Reporting-Standards_2020symposium.pdf
44. Raman, S. R., O'Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>
45. Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., ... Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*, 111(1), 283–292. <https://doi.org/10.1002/cpt.2453>
46. Sola-Morales, O., Curtis, L. H., Heidt, J., Walsh, L., Casso, D., Oliveria, S., Saunders-Hastings, P., Song, Y., Mercado, T., Zusterzeel, R., Mastey, V., Harnett, J., & Quek, R. G. W. (n.d.). Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory & HTA Decisions. *Clinical Pharmacology & Therapeutics*, n/a(n/a). <https://doi.org/10.1002/cpt.2914>
47. Solà-Morales, O., Sigurðardóttir, K., Akehurst, R., Murphy, L. A., Mestre-Ferrandiz, J., Cunningham, D., & de Pouvourville, G. (2023). Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. *Value in Health*, 26(4, Supplement), 32–42. <https://doi.org/10.1016/j.jval.2023.02.012>
48. Tadrous, M., Aves, T., Fahim, C., Riad, J., Mittmann, N., Prieto-Alhambra, D., Rivera, D. R., Chan, K., Lix, L. M., Kent, S., Dawoud, D., Guertin, J. R., McDonald, J. T., Round, J., Klarenbach, S., Stanojevic, S., De Vera, M. A., Strumpf, E., Platt, R. W., ... Hayes, K. N. (2024). Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making. *Journal of Clinical Epidemiology*, 176, 111545. <https://doi.org/10.1016/j.jclinepi.2024.111545>
49. van den Heuvel, T., Castañeda, J., Arrieta, A., Voelker, B., Cohen, O., Liu, M., Diaz Garelli, F., & Shin, J. (2024). Generating real-world evidence on diabetes technology using the CareLink Personal data management system. *Diabetes, Obesity and Metabolism*, 26(11), 4846–4853. <https://doi.org/10.1111/dom.15868>

50. Wang, J., Chen, J., Zhao, J., Wu, Y., Xin, X., & Chen, P. (2024). Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*.
<https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>
51. Wang, S. V., & Schneeweiss, S. (2022). A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data. *Clinical Epidemiology*, *14*, 601–608.
<https://doi.org/10.2147/CLEP.S358583>
52. 章太郎前田, 香苗東郷, 武蔵石黒, 貴之井上, 武彦坂本, 公寿菅野, & 充弘近藤. (2019). 本邦の医薬品開発におけるビッグデータ・リアルワールドデータの利活用に関する実態調査—日本製薬工業協会加盟各社に対するアンケート調査—. *臨床薬理*, *50*(4), 167–175.
<https://doi.org/10.3999/jscpt.50.167>
53. 雅俊谷川, 健一中野, 吉博青柳, & 英人横井. (2021). 「医療情報システム」における電磁的記録の薬事利用への対応—コンピュータ化システムの品質マネジメント—. *医療情報学*, *41*(3), 143–153. <https://doi.org/10.14948/jami.41.143>
54. 香苗東郷, 真也川松, 亮木口, & 康彦今井. (2019). 医薬品開発におけるリアルワールドデータ活用への期待—製薬企業の視点より—. *薬剤疫学*, *24*(1), 19–30.
<https://doi.org/10.3820/jjpe.24.19>

Determining Real-World Data's Fitness for Use and the Role of Reliability

"The Data Reliability Paper" | Published September 2019

1. Al-Sahab, B., Leviton, A., Loddenkemper, T., Paneth, N., & Zhang, B. (2024). Biases in Electronic Health Records Data for Generating Real-World Evidence: An Overview. *Journal of Healthcare Informatics Research*, 8(1), 121–139. <https://doi.org/10.1007/s41666-023-00153-2>
2. Antunes, C. P. (2021). *A Regulação dos dispositivos de recolha e processamento de dados em saúde* [masterThesis]. <https://repositorio.ul.pt/handle/10451/52892>
3. Backenroth, D., Royce, T., Pinheiro, J., Samant, M., & Humblet, O. (2023). Considerations for pooling real-world data as a comparator cohort to a single arm trial: A simulation study on assessment of heterogeneity. *BMC Medical Research Methodology*, 23(1), 193. <https://doi.org/10.1186/s12874-023-02002-7>
4. *Best Practices For Evaluating The Relevance And Quality Of RWD*. (n.d.). Retrieved March 13, 2023, from <https://www.clinicalleader.com/doc/best-practices-for-evaluating-the-relevance-and-quality-of-rwd-0001>
5. Beyrer, J., Abedtash, H., Hornbuckle, K., & Murray, J. F. (2022). A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*, 11(7), 499–511. <https://doi.org/10.2217/cer-2022-0006>
6. Boikos, C., Imran, M., De Lusignan, S., Ortiz, J. R., Patriarca, P. A., & Mansi, J. A. (2022). Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines*, 10(5), Article 5. <https://doi.org/10.3390/vaccines10050727>
7. Boyle, J. M., Hegarty, G., Frampton, C., Harvey-Jones, E., Dodkins, J., Beyer, K., George, G., Sullivan, R., Booth, C., & Aggarwal, A. (2021). Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study. *European Journal of Cancer*, 155, 136–144. <https://doi.org/10.1016/j.ejca.2021.07.001>
8. Burns, L., Kalesnik-Orszulak, R., Spring, R., Zeegers, F., Rutstein, M., Hukkelhoven, M., Wruck, L., & O'Donnell, J. (2022). Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies. *Advances in Therapy*, 39(10), 4772–4778. <https://doi.org/10.1007/s12325-022-02257-4>
9. Castellanos, E. H., Wittmershaus, B. K., & Chandwani, S. (2024). Raising the Bar for Real-

- World Data in Oncology: Approaches to Quality Across Multiple Dimensions. *JCO Clinical Cancer Informatics*, 8, e2300046. <https://doi.org/10.1200/CCI.23.00046>
10. Chen, J., Li, X. (Nicole), Lu, C. (Cindy), Yuan, S., Yung, G., Ye, J., Tian, H., & Lin, J. (n.d.). Considerations for master protocols using external controls. *Journal of Biopharmaceutical Statistics*, 1–23. <https://doi.org/10.1080/10543406.2024.2311248>
 11. Clay, I., Cormack, F., Fedor, S., Foschini, L., Gentile, G., Hoof, C. van, Kumar, P., Lipsmeier, F., Sano, A., Smarr, B., Vandendriessche, B., & Luca, V. D. (2022). Measuring Health-Related Quality of Life With Multimodal Data: Viewpoint. *Journal of Medical Internet Research*, 24(5), e35951. <https://doi.org/10.2196/35951>
 12. Cocoros, N. M., Arlett, P., Dreyer, N. A., Ishiguro, C., Iyasu, S., Sturkenboom, M., Zhou, W., & Toh, S. (2021). The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. *Clinical Pharmacology & Therapeutics*, 109(5), 1189–1196. <https://doi.org/10.1002/cpt.2045>
 13. Crane, G., Lim, J. C. W., Gau, C.-S., Xie, J., & Chu, L. (2022). The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: Expert panel recommendations. *Current Medical Research and Opinion*, 38(9), 1543–1551. <https://doi.org/10.1080/03007995.2022.2096354>
 14. Csoke, E., Landes, S., Francis, M. J., Ma, L., Teotico Pohlhaus, D., & Anquez-Traxler, C. (2022). How can real-world evidence aid decision making during the life cycle of nonprescription medicines? *Clinical and Translational Science*, 15(1), 43–54. <https://doi.org/10.1111/cts.13129>
 15. Daubner-Bendes, R., Kovács, S., Niewada, M., Huic, M., Drummond, M., Ciani, O., Blankart, C. R., Mandrik, O., Torbica, A., Yfantopoulos, J., Petrova, G., Holownia-Voloskova, M., Taylor, R. S., Al, M., Piniashko, O., Lorenzovici, L., Tarricone, R., Zemlányi, A., & Kaló, Z. (2021). Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Frontiers in Public Health*, 8. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.612410>
 16. Derman, B. A., Belli, A. J., Battiwalla, M., Hamadani, M., Kansagra, A., Lazarus, H. M., & Wang, C.-K. (2022). Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. *Blood Reviews*, 53, 100913. <https://doi.org/10.1016/j.blre.2021.100913>
 17. Dreyer, N. A., Hall, M., & Christian, J. B. (2020). Modernizing Regulatory Evidence with Trials and Real-World Studies. *Therapeutic Innovation & Regulatory Science*, 54(5), 1112–1115. <https://doi.org/10.1007/s43441-020-00131-5>

18. *External Controls in Research: The “What, Why and How.”* (2021, May 27). UBC.
<https://ubc.com/external-controls-in-research/>
19. Fleurence, R. L., Kent, S., Adamson, B., Tcheng, J., Balicer, R., Ross, J. S., Haynes, K., Muller, P., Campbell, J., Bouée-Benhamiche, E., García Martí, S., & Ramsey, S. (2024). Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force. *Value in Health*, 27(6), 692–701. <https://doi.org/10.1016/j.jval.2024.01.019>
20. Goldsack, J. C., Dowling, A. V., Samuelson, D., Patrick-Lake, B., & Clay, I. (2021). Evaluation, Acceptance, and Qualification of Digital Measures: From Proof of Concept to Endpoint. *Digital Biomarkers*, 5(1), 53–64. <https://doi.org/10.1159/000514730>
21. Gressler, L. E., Avila-Tang, E., Mao, J., Avalos-Pacheco, A., Shaya, F. T., Torosyan, Y., Liebeskind, A., Kinard, M., Mack, C. D., Normand, S.-L., Ritchey, M. E., & Marinac-Dabic, D. (2024). Data sources and applied methods for paclitaxel safety signal discernment. *Frontiers in Cardiovascular Medicine*, 10. <https://doi.org/10.3389/fcvm.2023.1331142>
22. Gressler, L. E., Marinac-Dabic, D., Resnic, F. S., Williams, S., Yang, K., Weichold, F., Avila-Tang, E., Mack, C., Coplan, P., Panagiotou, O. A., & Pappas, G. (2024). A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks. *Therapeutic Innovation & Regulatory Science*. <https://doi.org/10.1007/s43441-024-00680-z>
23. He, W., Fang, Y., Wang, H., & Chan, I. (2023). Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*, 15(1), 57–68.
<https://doi.org/10.1080/19466315.2021.1927827>
24. He, W., Zhang, Z., & Dharmarajan, S. (2023). Assessment of Fit-for-Use Real-World Data Sources and Applications. In W. He, Y. Fang, & H. Wang (Eds.), *Real-World Evidence in Medical Product Development* (pp. 45–61). Springer International Publishing.
https://doi.org/10.1007/978-3-031-26328-6_4
25. Hiramatsu, K., Barrett, A., Miyata, Y., & PhRMA Japan Medical Affairs Committee Working Group 1. (2021). Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. *Drugs - Real World Outcomes*, 8(4), 459–480. <https://doi.org/10.1007/s40801-021-00266-3>
26. Inan, O. T., Tenaerts, P., Prindiville, S. A., Reynolds, H. R., Dizon, D. S., Cooper-Arnold, K., Turakhia, M., Pletcher, M. J., Preston, K. L., Krumholz, H. M., Marlin, B. M., Mandl, K. D., Klasnja, P., Spring, B., Iturriaga, E., Campo, R., Desvigne-Nickens, P., Rosenberg, Y.,

- Steinhubl, S. R., & Califf, R. M. (2020). Digitizing clinical trials. *Npj Digital Medicine*, 3(1), Article 1. <https://doi.org/10.1038/s41746-020-0302-y>
27. Jackson, M. L., Manickam, R., Derieg, D., Gombar, S., & Low, Y. S. (2024). *Quantifying Fit-for-Purpose in Real World Data: Data Grading and FitQ Scores* (p. 2024.02.02.24302239). medRxiv. <https://doi.org/10.1101/2024.02.02.24302239>
28. Jaksá, A., Arena, P. J., Chan, K. K. W., Ben-Joseph, R. H., Jónsson, P., & Campbell, U. B. (2022). Transferability of real-world data across borders for regulatory and health technology assessment decision-making. *Frontiers in Medicine*, 9. <https://www.frontiersin.org/articles/10.3389/fmed.2022.1073678>
29. Jaksá, A., Wu, J., Jónsson, P., Eichler, H.-G., Vititoe, S., & Gatto, N. M. (2021). Organized structure of real-world evidence best practices: Moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*, 10(9), 711–731. <https://doi.org/10.2217/ce-2020-0228>
30. Jiu, L., Hartog, M., Wang, J., Vreman, R. A., Klungel, O. H., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Tools for assessing quality of studies investigating health interventions using real-world data: A literature review and content analysis. *BMJ Open*, 14(2), e075173. <https://doi.org/10.1136/bmjopen-2023-075173>
31. Kataria, S., & Ravindran, V. (2022). Harnessing of real-world data and real-world evidence using digital tools: Utility and potential models in rheumatology practice. *Rheumatology*, 61(2), 502–513. <https://doi.org/10.1093/rheumatology/keab674>
32. Kaushal D. Desai, Matthew W. Reynolds, Jennifer B. Christian, & Hossein Estiri. (2021). Fit-for-Purpose Real-World Data Assessments in Oncology: A Call for Cross-Stakeholder Collaboration. *Value and Outcomes Spotlight*, 7(3). <https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/expanding-the-value-conversation/fit-for-purpose-real-world-data-assessments-in-oncology-a-call-for-cross-stakeholder-collaboration>
33. Kehoe, L., Locke, T., McClellan, M., Landray, M., Hernandez, A., & Okun, S. (2024). Overcoming the barriers to better evidence generation from clinical trials. *Trials*, 25(1), 614. <https://doi.org/10.1186/s13063-024-08460-8>
34. Klimek, P., Baltic, D., Brunner, M., Degelsegger-Marquez, A., Garhöfer, G., Gouya-Lechner, G., Herzog, A., Jilma, B., Kähler, S., Mikl, V., Mraz, B., Ostermann, H., Röhl, C., Scharinger, R., Stamm, T., Strassnig, M., Wirthumer-Hoche, C., & Pleiner-Duxneuner, J. (2022). Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus. *JMIR Medical Informatics*, 10(6), e34204.

<https://doi.org/10.2196/34204>

35. Lentz, T. A., Curtis, L. H., Rockhold, F. W., Martin, D., Andersson, T. L. G., Arias, C., Berlin, J. A., Binns, C., Cook, A., Cziraky, M., Dent, R., Desai, M., Emmett, A., Esserman, D., George, J., Hantel, S., Heagerty, P., Hernandez, A. F., Hucko, T., ... Ellenberg, S. S. (2020). Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. *Therapeutic Innovation & Regulatory Science*, 54(6), 1477–1488. <https://doi.org/10.1007/s43441-020-00175-7>
36. Levenson, M., He, W., Chen, L., Dharmarajan, S., Izem, R., Meng, Z., Pang, H., & Rockhold, F. (2022). Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development. *Statistics in Biopharmaceutical Research*, 0(0), 1–8. <https://doi.org/10.1080/19466315.2022.2120533>
37. Li, X., Lo Re III, V., & Toh, S. (2022). Profiling real-world data sources for pharmacoepidemiologic research: A call for papers. *Pharmacoepidemiology and Drug Safety*, 31(9), 929–931. <https://doi.org/10.1002/pds.5481>
38. Ligang Luo, Pingyan Chen, Jianing Di, Jun Wang, & Chunquan Ou. (2021, April). *Guideline on Using Real-World Data to Generate Real-World Evidence (Trial Version)*. Center for Drug Evaluation, NMPA. <http://www.gdbiost.org/uploads/files/%E3%80%8AGuideline%20on%20Using%20Real-World%20Data%20to%20Generate%20Real-World%20Evidence%E3%80%8B-RWD%E8%AF%95%E8%A1%8C.pdf>
39. Luca Foschini, Bray Patrick-Lake, Anusha Narayan, & Mikki Nasch. (2022). *Next Generation Patient Engagment & Enriched Insights: Increasing Confidence in Person-Generated Health Data (PGHD) and its Impact on Clinical Decision Making*. evalidation. https://pages.evalidation.com/hubfs/Evalidation%20Next%20Generation%20Patient%20Engagement%20&%20Enriched%20Insights_May%202022.pdf
40. Lydia Wenxin Lin, Jeonghoon Ahn, Diana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Wandrudee Isaranuwatjai, Sarin KC, Brendon Kearney, Jing Lou, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh-Fang PWU, Asrul Akmal Shafie, Yot Teerawattananon, Sean Tunis, Hui-Min Wu, John Zalcborg, & Hwee-Lin Wee. (2020, November 1). *Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia*. REALISE Group. https://hiper.nus.edu.sg/wp-content/uploads/2021/03/REALISE-Full-guidance-post-feedback_20201211-version-1.1.pdf
41. Makhmutova, M. (Ed.). (2021). *Predicting changes in depression using person-generated*

health data.

42. Marc Berger, James Li, William Crown, & Kelly Zou. (2023). *ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making*. <https://doi.org/10.21203/rs.3.rs-3025202/v1>
43. Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas Harisson, Adam Aten, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, September 26). *Determining Real-World Data's Fitness for Use and the Role of Reliability*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>
44. O'Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
45. Orsini, L. S., Berger, M., Crown, W., Daniel, G., Eichler, H.-G., Goettsch, W., Graff, J., Guerino, J., Jonsson, P., Lederer, N. M., Monz, B., Mullins, C. D., Schneeweiss, S., Brunt, D. V., Wang, S. V., & Willke, R. J. (2020). Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. *Value in Health*, 23(9), 1128–1136. <https://doi.org/10.1016/j.jval.2020.04.002>
46. Rachael L. DiSantostefano, Erica A Voss, & Clair Blacketer. (2020). *"Fake News" in the Rush to Inform on COVID-19: How Research Retraction Can Inform Best Practices for Real-World Data Quality and Reporting*. Janssen Research and Development. https://www.ohdsi.org/wp-content/uploads/2020/10/DiSantostefano-Abstract_COVID19-Retractions-Inform-RWD-Quality-and-Reporting-Standards_2020symposium.pdf
47. Raman, S. R., O'Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>
48. *Regulatory considerations on artificial intelligence for health*. (2022, September). ITU Publications. https://www.itu.int/dms_pub/itu-t/opb/fg/T-FG-AI4H-2022-3-PDF-E.pdf
49. Reynolds, M. W., Bourke, A., & Dreyer, N. A. (2020). Considerations when evaluating real-world data quality in the context of fitness for purpose. *Pharmacoepidemiology and*

Drug Safety, 29(10), 1316–1318. <https://doi.org/10.1002/pds.5010>

50. Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., ... Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*, 111(1), 283–292. <https://doi.org/10.1002/cpt.2453>
51. Ru, B., Sillah, A., Desai, K., Chandwani, S., Yao, L., & Kothari, S. (2024). Real-World Data Quality Framework for Oncology Time to Treatment Discontinuation Use Case: Implementation and Evaluation Study. *JMIR Medical Informatics*, 12(1), e47744. <https://doi.org/10.2196/47744>
52. Ryan J. Shaw, Mina Boazak, Victoria Tiase, Gloria Porter, Jedrek Wosik, Sarah Bumatay, LeAnn Michaels, Julie Stone, Deborah Cohen, & Rowena Dolor. (2021, May). *Integrating Patient-Generated Digital Health Data into Electronic Health Records in Ambulatory Care Settings: An Environmental Scan*. Agency for healthcare Research and Quality. https://www.researchgate.net/profile/Gloria-Porter/publication/356105655_Environmental_Scan_Report_Integrating_Patient-Generated_Digital_Health_Data_into_Electronic_Health_Records_in_Ambulatory_Care_Settings_An_Environmental_Scan/links/618be95961f09877207a85e7/Environmental-Scan-Report-Integrating-Patient-Generated-Digital-Health-Data-into-Electronic-Health-Records-in-Ambulatory-Care-Settings-An-Environmental-Scan.pdf
53. Sengupta, S., Ntambwe, I., Tan, K., Liang, Q., Paulucci, D., Castellanos, E., Fiore, J., Lane, S., Micsinai Balan, M., Viraswami-Apanna, K., Sethuraman, V., Samant, M., & Tiwari, R. (2023). Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study. *Clinical Pharmacology & Therapeutics*, 113(4), 867–877. <https://doi.org/10.1002/cpt.2841>
54. Solà-Morales, O., Sigurðardóttir, K., Akehurst, R., Murphy, L. A., Mestre-Ferrandiz, J., Cunningham, D., & de Pouvourville, G. (2023). Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. *Value in Health*. <https://doi.org/10.1016/j.jval.2023.02.012>
55. Sudha R. Raman, Suzanne N. Landi, Jennifer L. Lund, & Michele Jonsson Funk. (2021). Approaches to mitigate bias in the design and analysis of pRCTs. In *Pragmatic Randomized Clinical Trials: Using Primary Data Collection and Electronic Health Records* (pp. 131–149).
56. Swaminathan, A. C., Snyder, L. D., Hong, H., Stevens, S. R., Long, A. S., Yanchenko, E.,

- Qiu, Y., Liu, R., Zhang, H., Fischer, A., Burns, L., Wruck, L. M., & Palmer, S. M. (2023). External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. *American Journal of Respiratory and Critical Care Medicine*, 208(5), 579–588. <https://doi.org/10.1164/rccm.202210-1947OC>
57. Tadrous, M., Aves, T., Fahim, C., Riad, J., Mittmann, N., Prieto-Alhambra, D., Rivera, D. R., Chan, K., Lix, L. M., Kent, S., Dawoud, D., Guertin, J. R., McDonald, J. T., Round, J., Klarenbach, S., Stanojevic, S., De Vera, M. A., Strumpf, E., Platt, R. W., ... Hayes, K. N. (2024). Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making. *Journal of Clinical Epidemiology*, 176, 111545. <https://doi.org/10.1016/j.jclinepi.2024.111545>
58. Thompson, D. (2021). Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? *Value in Health*, 24(1), 112–115. <https://doi.org/10.1016/j.jval.2020.09.015>
59. Wang, J., Chen, J., Zhao, J., Wu, Y., Xin, X., & Chen, P. (2024). Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>
60. Zou, K. H., & Berger, M. L. (2024). Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union. *Bioengineering*, 11(8), Article 8. <https://doi.org/10.3390/bioengineering11080784>
61. Zura, R., Irwin, D. E., Mack, C. D., Aldridge, M. L., & Mackowiak, J. I. (2021). Real-World Evidence: A Primer. *Journal of Orthopaedic Trauma*, 35, S1. <https://doi.org/10.1097/BOT.0000000000002037>

Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility

“The Credibility Paper” | Published November 2019

1. Dang LE, Gruber S, Lee H, et al. A Causal Roadmap for Generating High-Quality Real-World Evidence. Published online May 11, 2023. doi:10.48550/arXiv.2305.06850
2. Beyrer J, Abedtash H, Hornbuckle K, Murray JF. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*. 2022;11(7):499-511. doi:10.2217/cer-2022-0006
3. He W, Fang Y, Wang H, Chan I. Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*. 2023;15(1):57-68. doi:10.1080/19466315.2021.1927827
4. He W, Zhang Z, Dharmarajan S. Assessment of Fit-for-Use Real-World Data Sources and Applications. In: He W, Fang Y, Wang H, eds. *Real-World Evidence in Medical Product Development*. Springer International Publishing; 2023:45-61. doi:10.1007/978-3-031-26328-6_4
5. Marc Berger, James Li, William Crown, Kelly Zou. ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making. Published online June 7, 2023. doi:<https://doi.org/10.21203/rs.3.rs-3025202/v1>
6. Mack CD, Pavesio A, Kelly K, et al. Breaking Barriers: Studying Fracture Healing in the BONES Program. *Journal of Orthopaedic Trauma*. 2021;35:S22. doi:10.1097/BOT.0000000000002035
7. Yukari Uemura, Ryoto Ozaki, Tomohiro Shinozaki, Hiroshi Ohtsu. Comparative Effectiveness of Tocilizumab vs Standard Care in Patients with severe COVID-19–related Pneumonia: A retrospective cohort study utilizing registry data as a synthetic control. doi:10.21203/rs.3.rs-2866088/v1
8. Lauren Elizabeth Eyler Dang. *Development and Application of the Experiment-Selector Cross-Validated Targeted Maximum Likelihood Estimator*. University of California, Berkeley; 2023. Accessed March 6, 2024. <https://www.proquest.com/docview/2869145998?pq-origsite=gscholar&fromopenview=true&sourcetype=Dissertations%20&%20Theses>

9. O'Donnell JC, Le TK, Dobrin R, et al. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. *Future Oncology*. 2021;17(3):333-347. doi:10.2217/fon-2020-0591
10. Carrigan G, Bradbury BD, Brookhart MA, et al. External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges. *Curr Epidemiol Rep*. 2022;9(4):326-337. doi:10.1007/s40471-022-00305-9
11. Shau WY, Setia S, Shinde S, Santoso H, Furtner D. Generating fit-for-purpose real-world evidence in Asia: How far are we from closing the gaps? *Perspect Clin Res*. 2023;14(3):108-113. doi:10.4103/picr.picr_193_22
12. Dreyer NA, Hall M, Christian JB. Modernizing Regulatory Evidence with Trials and Real-World Studies. *Ther Innov Regul Sci*. 2020;54(5):1112-1115. doi:10.1007/s43441-020-00131-5
13. Fisher VA, Comment LA. Multi-state survival models with treatment effects and biomarkers: Simulations for study design assessment. *Cancer Epidemiology*. 2022;81:102272. doi:10.1016/j.canep.2022.102272
14. Jaks A, Wu J, Jónsson P, Eichler HG, Vittoe S, Gatto NM. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*. 2021;10(9):711-731. doi:10.2217/cer-2020-0228
15. Acha V, Barefoot B, Juarez Garcia A, et al. Principles for Good Practice in the Conduct of Non-interventional Studies: The View of Industry Researchers. *Ther Innov Regul Sci*. Published online July 17, 2023. doi:10.1007/s43441-023-00544-y
16. Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA. Real-world evidence to support regulatory decision making: New or expanded medical product indications. *Pharmacoepidemiology and Drug Safety*. 2021;30(6):685-693. doi:10.1002/pds.5222
17. Sheffield KM, Dreyer NA, Murray JF, Faries DE, Klopchin MN. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions. *Journal of Comparative Effectiveness Research*. 2020;9(15):1043-1050. doi:10.2217/cer-2020-0161
18. Murphy LA, Akehurst R, Solà-Morales O, et al. Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers. *Value in Health*. 2023;26(4, Supplement):20-31. doi:10.1016/j.jval.2023.01.007

19. Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, et al. Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility. Published online November 25, 2019. <https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world>
20. Wherry K, Stromberg K, Hinnenthal JA, Wallenfelsz LA, El-Chami MF, Bockstedt L. Using Medicare Claims to Identify Acute Clinical Events Following Implantation of Leadless Pacemakers. *Pragmat Obs Res*. 2020;11:19-26. doi:10.2147/POR.S240913
21. Broek RWM van den, Matheis RJ, Bright JL, Hartog TE, Perfetto EM. Value-based evidence across health care sectors: a push for transparent real-world studies, data, and evidence dissemination. *Health Economics, Policy and Law*. 2022;17(4):416-427. doi:10.1017/S1744133122000056

Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness

“The Totality of Evidence Paper” | Published December 2019

1. *A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2- Metastatic Breast Cancer.* (n.d.). Jadpro. Retrieved November 27, 2024, from <https://jadpro.com/online-first/2024/a-real-world-evidence-primer-for-advanced-practice-providers-integrating-p-reality-x-into-shared-decision-making-for-people-with-hrplusher2-metastatic-breast-cancer/>
2. Beena Bhuiyan Khan. (2021, August 11). *View Public Comments for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (CAG-00460N).*
3. Boikos, C., Imran, M., De Lusignan, S., Ortiz, J. R., Patriarca, P. A., & Mansi, J. A. (2022). Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines, 10*(5), Article 5. <https://doi.org/10.3390/vaccines10050727>
4. Boikos, C., McGovern, I., Molrine, D., Ortiz, J. R., Puig-Barberà, J., & Haag, M. (2022). Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. *Vaccines, 10*(6), Article 6. <https://doi.org/10.3390/vaccines10060896>
5. Boikos, C., McGovern, I., Ortiz, J. R., Puig-Barberà, J., Versage, E., & Haag, M. (2022). Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States. *Vaccines, 10*(9), Article 9. <https://doi.org/10.3390/vaccines10091456>
6. Bourla, A. B., & Herrmann, K. (2021). Real-World Data as an Evidence Source in Nuclear Medicine. *Journal of Nuclear Medicine, 62*(2), 156–157. <https://doi.org/10.2967/jnumed.120.258665>
7. Burns, L., Le Roux, N., Kalesnik-Orszulak, R., Christian, J., Dudinak, J., Rockhold, F., Khozin, S., & O’Donnell, J. (2023). Real-world evidence for regulatory decision-making: Updated guidance from around the world. *Frontiers in Medicine, 10*, 1236462. <https://doi.org/10.3389/fmed.2023.1236462>
8. *Contemporary Applications of Real-World Evidence in Regulatory Decision Making: A Case Series Review – Medical Affairs Professional Society.* (n.d.). Retrieved December 8, 2022, from <https://medicalaffairs.org/real-world-evidence-regulatory-decision-making/>
9. Dreyer, N. A., Hall, M., & Christian, J. B. (2020). Modernizing Regulatory Evidence with Trials and Real-World Studies. *Therapeutic Innovation & Regulatory Science, 54*(5), 1112–

1115. <https://doi.org/10.1007/s43441-020-00131-5>

10. Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2022). Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019. *Clinical Pharmacology & Therapeutics*, 111(1), 310–320. <https://doi.org/10.1002/cpt.2462>
11. Evgenia Alekseevna. (2022). *PHARMACOEPIDEMIOLOGICAL AND CLINICAL AND ECONOMIC EVALUATION OF PSORIASIS THERAPY IN REAL PRACTICE IN THE RUSSIAN FEDERATION* [Federal State Autonomous Educational Institution higher education “Peoples’ Friendship University of Russia”]. https://www.volgmed.ru/uploads/dsovet/thesis/2-993-novoderezhkina_evgeniya_alekseevna.pdf
12. Fleurence, R. L., Kent, S., Adamson, B., Tcheng, J., Balicer, R., Ross, J. S., Haynes, K., Muller, P., Campbell, J., Bouée-Benhamiche, E., García Martí, S., & Ramsey, S. (2024). Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force. *Value in Health*, 27(6), 692–701. <https://doi.org/10.1016/j.jval.2024.01.019>
13. Girman, C. J., Ritchey, M. E., McNeill, A. M., Sundell, K. A., & Meyer, R. J. (2021). Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims. *Therapeutic Innovation & Regulatory Science*, 55(3), 561–567. <https://doi.org/10.1007/s43441-020-00252-x>
14. James A Rogers, Hugo Maas, & Alejandro Perez. (2022, October). *Analysis Planning and Interpretation Using Causal Directed Acyclic Graphs: A Case Study in Oncology*. <https://metrumrg.com/wp-content/uploads/2022/10/dags-acop2022-poster.pdf>
15. Kugener, V. F., Freedland, E. S., Maynard, K. I., Aimer, O., Webster, P. S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. *Drug Safety*, 44(8), 843–852. <https://doi.org/10.1007/s40264-021-01078-8>
16. Lynch, H. F., & Bateman-House, A. (2020). Facilitating Both Evidence and Access: Improving FDA’s Accelerated Approval and Expanded Access Pathways. *Journal of Law, Medicine & Ethics*, 48(2), 365–372. <https://doi.org/10.1177/1073110520935352>
17. Mack, C. D., Pavesio, A., Kelly, K., Irwin, D. E., Maislin, G., Jones, J., Wester, T., & Zura, R. (2021). Breaking Barriers: Studying Fracture Healing in the BONES Program. *Journal of Orthopaedic Trauma*, 35, S22. <https://doi.org/10.1097/BOT.0000000000002035>
18. Mahendraratnam, N., Mercon, K., Gill, M., Benzing, L., & McClellan, M. B. (2022).

- Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness. *Clinical Pharmacology & Therapeutics*, 111(1), 150–154. <https://doi.org/10.1002/cpt.2272>
19. McDermott, O., & Kearney, B. (n.d.). The value of using real-world evidence as a source of clinical evidence in the European medical device regulations: A mixed methods study. *Expert Review of Medical Devices*, 1–15. <https://doi.org/10.1080/17434440.2023.2291454>
 20. Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam Kroetsch, Katherine Frank, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, December 19). *Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product>
 21. Novoderezhkina, E. A., & Zyryanov, S. K. (2022). The role of real world data and real world evidence in health technology assessment. *FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology*, 15(3), Article 3. <https://doi.org/10.17749/2070-4909/farmakoeconomika.2022.120>
 22. Novoderezhkina, E. A., Алексеевна, Н. Е., Zyryanov, S. K., & Кенсаринович, З. С. (2021). THE ROLE OF REAL CLINICAL PRACTICE DATA IN MODERN HEALTHCARE. *Farmaciya (Pharmacy)*, 70(3), Article 3. <https://doi.org/10.29296/25419218-2021-03-01>
 23. Reed, S. D., & McLeod, L. (2020). Moving Beyond the Tip of the Iceberg to Incorporate Patients' Perspectives and Outcomes in the Medical Device Regulatory Process. *Value in Health*, 23(3), 298–299. <https://doi.org/10.1016/j.jval.2020.01.008>
 24. Reynolds, M. W., Bourke, A., & Dreyer, N. A. (2020). Considerations when evaluating real-world data quality in the context of fitness for purpose. *Pharmacoepidemiology and Drug Safety*, 29(10), 1316–1318. <https://doi.org/10.1002/pds.5010>
 25. Sarri, G., Patorno, E., Yuan, H., Guo, J. (Jeff), Bennett, D., Wen, X., Zullo, A. R., Largent, J., Panaccio, M., Gokhale, M., Moga, D. C., Ali, M. S., & Debray, T. P. A. (2022). Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evidence-Based Medicine*, 27(2), 109–119. <https://doi.org/10.1136/bmjebm-2020-111493>
 26. Wang, J., Chen, J., Zhao, J., Wu, Y., Xin, X., & Chen, P. (2024). Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*.

<https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>

27. Zou, K. H., Li, J. Z., Imperato, J., Potkar, C. N., Sethi, N., Edwards, J., & Ray, A. (2020). Harnessing Real-World Data for Regulatory Use and Applying Innovative Applications. *Journal of Multidisciplinary Healthcare*, 13, 671–679. <https://doi.org/10.2147/JMDH.S262776>
28. НОВОДЕРЕЖКИНА Е.А. & ЗЫРЯНОВ С.К. (2020). Роль данных реальной клинической практики в современном здравоохранении. 5–10. <https://doi.org/10.29296/25419218-2021-03-01>

A Roadmap for Developing Study Endpoints in Real-World Settings

“The RWE Endpoints Paper” | Published August 2020

1. Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, et al. A Roadmap for Developing Study Endpoints in Real-World Settings. Published online August 28, 2020. <https://healthpolicy.duke.edu/publications/roadmap-developing-study-endpoints-real-world-settings>
2. Stern AD, Brönneke J, Debatin JF, et al. Advancing digital health applications: priorities for innovation in real-world evidence generation. *The Lancet Digital Health*. 2022;4(3):e200-e206. doi:10.1016/S2589-7500(21)00292-2
3. He W, Fang Y, Wang H, Chan I. Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*. 2021;0(0):1-12. doi:10.1080/19466315.2021.1927827
4. Sola-Morales O, Curtis LH, Heidt J, et al. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory & HTA Decisions. *Clinical Pharmacology & Therapeutics*. n/a(n/a). doi:10.1002/cpt.2914
5. Wang J, Chen J, Zhao J, Wu Y, Xin X, Chen P. Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*. Published online March 17, 2024. Accessed June 4, 2024. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>
6. Chen J, Scharfstein D, Wang H, et al. Estimands in Real-World Evidence Studies. *Statistics in Biopharmaceutical Research*.:1-13. doi:10.1080/19466315.2023.2259829
7. Jaksa A, Bloudek L, Carlson JJ, et al. Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot. *International Journal of Technology Assessment in Health Care*. 2022;38(1):e32. doi:10.1017/S0266462322000162
8. Jaksa A, Mahendraratnam N. Learning from the past to advance tomorrow's real-world evidence: what demonstration projects have to teach us. *Journal of Comparative Effectiveness Research*. 2021;10(16):1169-1173. doi:10.2217/cer-2021-0166
9. Burns L, Roux NL, Kalesnik-Orszulak R, et al. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World. *Clinical Therapeutics*. 2022;44(3):420-437. doi:10.1016/j.clinthera.2022.01.012
10. Alipour-Haris G, Liu X, Acha V, Winterstein AG, Burcu M. Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases. *Clinical and Translational Science*. 2024;17(8):e13903. doi:10.1111/cts.13903

11. Beyrer J. *Regulatory Acceptable Real-World Effectiveness Endpoints: How Clarity Can Best Be Achieved in the United States*. Ph.D. Indiana University - Purdue University Indianapolis; 2023. Accessed March 6, 2024.
<https://www.proquest.com/docview/2908925189/abstract/2FBBFAB790144CA3PQ/1>
12. Cottu P, Ramsey SD, Solà-Morales O, Spears PA, Taylor L. The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making. *The Breast*. 2022;61:118-122. doi:10.1016/j.breast.2021.12.015
13. Rivera DR, Henk HJ, Garrett-Mayer E, et al. The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*. 2022;111(1):283-292. doi:10.1002/cpt.2453
14. Khambholja K, Gehani M. Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review. *Value in Health*. 2023;26(3):427-434. doi:10.1016/j.jval.2022.09.003

Point-of-Care Clinical Trials: Integrating Research and Care Delivery

“The POC Paper” | Published May 2022

1. Bahls, C. (2022). “Record” Gains in Bringing Research Closer to the Patient. *Applied Clinical Trials*, 31(9), 19–22.
2. Burns, L., Le Roux, N., Kalesnik-Orszulak, R., Christian, J., Dudinak, J., Rockhold, F., Khozin, S., & O’Donnell, J. (2023). Real-world evidence for regulatory decision-making: Updated guidance from around the world. *Frontiers in Medicine*, 10, 1236462. <https://doi.org/10.3389/fmed.2023.1236462>
3. Caleigh Propes, Sarah Sheehan, & Rachele Hendricks-Sturup. (2022, May 11). *Point-of-Care Clinical Trials: Integrating Research and Care Delivery*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/point-care-clinical-trials-integrating-research-and-care-delivery>
4. Hau, C., Woods, P. A., Guski, A. S., Raju, S. I., Zhu, L., Alba, P. R., Cushman, W. C., Glassman, P. A., Ishani, A., Taylor, A. A., Ferguson, R. E., & Leatherman, S. M. (2024). Strategies for secondary use of real-world clinical and administrative data for outcome ascertainment in pragmatic clinical trials. *Journal of Biomedical Informatics*, 150, 104587. <https://doi.org/10.1016/j.jbi.2024.104587>
5. Hendricks-Sturup, R., & Francis, D. (2020). Evidence on Real-World Data and Real-World Evidence As a Driver for Precision Medicine Implementation in Pharmacy Practice. In *Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy* (pp. 1–12). Springer International Publishing. https://doi.org/10.1007/978-3-030-50247-8_93-1
6. Leatherman, S. M., & Ishani, A. (2024). Point of Care Clinical Trials in Nephrology. *Journal of the American Society of Nephrology*, 10.1681/ASN.0000000000000340. <https://doi.org/10.1681/ASN.0000000000000340>
7. Ridgeway, J. L., Sundt, W. J. S., Krpata, T. S., Glasgow, A., Smith, O. A., Lampman, M. A., Smith-Stellflug, J. L., Menser, T. L., Juntunen, M. B., Liedl, C. P., Hentz, J. G., McCoy, J. J., & McCoy, R. G. (2024). Evaluating adoption and reach in a pragmatic randomized trial of community paramedicine for intermediate acuity patient care. *Journal of Clinical and Translational Science*, 8(1), e199. <https://doi.org/10.1017/cts.2024.646>

Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Evidence Ecosystem

“The SEO Paper” | Published July 2022

1. Burns, L., Le Roux, N., Kalesnik-Orszulak, R., Christian, J., Dudinak, J., Rockhold, F., Khozin, S., & O'Donnell, J. (2023). Real-world evidence for regulatory decision-making: Updated guidance from around the world. *Frontiers in Medicine*, *10*, 1236462. <https://doi.org/10.3389/fmed.2023.1236462>
2. Dunger-Baldauf, C., Hemmings, R., Bretz, F., Jones, B., Schiel, A., & Holmes, C. (2023). Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs. *Clinical Pharmacology & Therapeutics*, *113*(5), 1132–1138. <https://doi.org/10.1002/cpt.2869>
3. Oberprieler, N. G., Pladevall-Vila, M., Johannes, C., Layton, J. B., Golozar, A., Lavallee, M., Liu, F., Kubin, M., & Vizcaya, D. (2024). FOUNTAIN: A modular research platform for integrated real-world evidence generation. *BMC Medical Research Methodology*, *24*(1), 224. <https://doi.org/10.1186/s12874-024-02344-w>
4. Rebecca Ray, Trevan Locke, & Rachele Hendricks-Sturup. (2022, July 20). *Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/aligning-shared-evidentiary-needs-among-payers-and-regulators-real-world-data>

Improving Patient Subgroup Representation with Real-World Data

“The Patients Subgroups Paper” | Published September 2023

1. Gressler LE, Marinac-Dabic D, Resnic FS, et al. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks. *Ther Innov Regul Sci*. Published online July 25, 2024. doi:10.1007/s43441-024-00680-z
2. Schoonenboom J. Design Patterns in Mixed Methods Research: Embedding Mixed Methods Matched Comparisons Sampling in Previous Design Decisions. *Journal of Mixed Methods Research*. 2024;18(3):383-392. doi:10.1177/15586898241257284

Lessons from Learning Health Care Systems and Recommendations for Successful Implementation

“The LHS Paper” | Published October 2023

1. D’Ambrosio M, Locke T, Hendricks-Sturup R. Addressing Climate Change-Induced Tick-borne Lyme Disease Patterns Through Data-Driven ‘One Health’ Policy. *Journal of Public Health Management and Practice*. 2024;30(4):E157. doi:10.1097/PHH.0000000000001975

Real-World Evidence to Support Causal Inference: Methodological Considerations for Non-Interventional Studies

“The Causal Inference Paper” | Published June 2024

1. Rippin, G., & Sanz, H. (2024). External comparator studies and the joint application of the estimand and target trial emulation frameworks. *Frontiers in Drug Safety and Regulation*, 4. <https://doi.org/10.3389/fdsfr.2024.1409102>